1 – 9 of 9
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
(
- Contribution to journal › Article
- 2019
-
Mark
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
(
- Contribution to journal › Article
- 2012
-
Mark
The Expression of β-Microseminoprotein but Not CRISP3 Is Reduced in Ovarian Cancer and Correlates to Survival.
(
- Contribution to journal › Article
- 2009
-
Mark
A model of the complex between human beta-microseminoprotein and CRISP-3 based on NMR data.
(
- Contribution to journal › Article
- 2007
-
Mark
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy
(
- Contribution to journal › Article
- 2006
-
Mark
Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland.
(
- Contribution to journal › Article
- 2004
-
Mark
Cysteine-rich secretory protein 3 is a ligand of alpha1B-glycoprotein in human plasma
(
- Contribution to journal › Article
- 2002
-
Mark
Identification of human cysteine-rich secretory protein 3 (CRISP-3) as a matrix protein in a subset of peroxidase-negative granules of neutrophils and in the granules of eosinophils
(
- Contribution to journal › Article
-
Mark
An ELISA for SGP28/CRISP-3, a cysteine-rich secretory protein in human neutrophils, plasma, and exocrine secretions
(
- Contribution to journal › Article